Vcanbio Cell & Gene Engineering Corp Dividend
Dividend of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 9, 2026.
Get this data via API
Financial Data API
Dividend
0.00CNY
Last updated:
How much dividend does Vcanbio Cell & Gene Engineering Corp 2026 pay?
According to the latest status from October 2026, Vcanbio Cell & Gene Engineering Corp paid a total of 0.00 CNY per share in dividends within the last 12 months. With the current Vcanbio Cell & Gene Engineering Corp price of 19.10 CNY, this corresponds to a dividend yield of - %. A dividend is paid times per year.
Historical Vcanbio Cell & Gene Engineering Corp Dividends
| Paydate | Dividend |
|---|---|
| 0.01CNY | |
| 0.05CNY | |
| 0.09CNY |
The Vcanbio Cell & Gene Engineering Corp Dividend history
3 Years
10 Years
25 Years
Max
| YEAR | Dividend | YoY |
|---|---|---|
| est | 0.00CNY | — |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — | |
| 0.00CNY | — |
Is the Vcanbio Cell & Gene Engineering Corp Dividend Safe?
Vcanbio Cell & Gene Engineering Corp has been increasing the dividend for 0 years.
Analysts expect a Dividend Cut of -100.00% for the current fiscal year.
Dividend Details
Understanding Vcanbio Cell & Gene Engineering Corp's Dividend Distributions
Vcanbio Cell & Gene Engineering Corp’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining Vcanbio Cell & Gene Engineering Corp's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
Vcanbio Cell & Gene Engineering Corp's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in Vcanbio Cell & Gene Engineering Corp’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Vcanbio Cell & Gene Engineering Corp paid dividends every year for the past 0 years.
Vcanbio Cell & Gene Engineering Corp is assigned to the 'Health' sector.
To receive the latest dividend of Vcanbio Cell & Gene Engineering Corp from 8/16/2001 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 8/10/2001.
The last dividend was paid out on 8/16/2001.
The dividends of Vcanbio Cell & Gene Engineering Corp are distributed in CNY.
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth